Boston Scientific (BSX) Tops Q1 EPS by 5c; Guides Above Views

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.56, $0.05 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.68 billion.

GUIDANCE:

Boston Scientific sees Q2 2024 EPS of $0.57-$0.59, versus the consensus of $0.56.

Boston Scientific sees FY2024 EPS of $2.29-$2.34, versus the consensus of $2.25.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
• Activist investor presses Xerox to review financial services arm - Bloomberg
• TD Cowen on Boston Scientific (BSX): 'Shipping Confirmed With Physician Contacts', 'We view the news as a big step forward'